Journal of Drug Targeting

Basic Information

Brief Name: J DRUG TARGET
Impact Factor: 4.3
ISSN: 1061-186X
Research Field: MEDICAL
h-index: 80
Self-citation Rate: 2.6%
Articles per Year: 69

SCI Index Status: Science Citation Index Expanded
Journal Website: https://www.tandfonline.com/journals/idrt20
Journal Introduction:

Journal of Drug Targeting is a subscription-based, peer-reviewed journal that publishes research on all aspects of drug delivery and targeting for molecular and macromolecular drugs including the design and characterization of carrier systems (whether colloidal, protein or polymeric) for both vitro and/or in vivo applications of these drugs. Papers are not restricted to drugs delivered by way of a carrier, but also include studies on molecular and macromolecular drugs that are designed to target specific cellular or extra-cellular molecules, as well as on the identification of novel drug targets. As such the journal publishes results on the activity, delivery and targeting of therapeutic peptides/proteins and nucleic acids including genes/plasmid DNA, RNA-based therapeutics (e.g. mRNA, microRNAs), gene-editing and gene silencing nucleic acids (e.g. small interfering (si)RNA, antisense oligonucleotides, ribozymes, DNAzymes), as well as small-molecule drugs, aptamers, mononucleotides and monoclonal antibodies and their conjugates. The diagnostic application of targeting technologies as well as targeted delivery of therapeutic, diagnostic and imaging agents also fall within the scope of the journal. In addition, papers are sought on self-regulating systems, systems responsive to their environment and to external stimuli and those that can produce programmed, pulsed and otherwise complex delivery patterns. Journal of Drug Targeting also carries papers on the physiological and other biological barriers to delivery and targeting, and means of overcoming the barriers, for example, by penetration enhancers, and covers subjects such as extravasation, diffusion in tumours and target tissues, avoidance of the reticulo-endothelial system, and toxicity testing and licensing of novel delivery systems. The journal’s audience includes, but is not limited to, scientists working in the pharmaceutical and biopharmaceutical sciences, drug delivery and targeting, molecular and biological sciences, pharmacology, toxicology, chemistry, and materials/polymer sciences. Journal of Drug Targeting welcomes for consideration the following types of article: original articles, reviews, article commentaries, book reviews, letters, communications, and method articles. All articles received by the Journal will be subject to single-anonymous peer review.

CiteScore

CiteScore
9.1
SJR
0.849
SNIP
0.706
Subject Rank Percentile
Pharmacology, Toxicology and PharmaceuticsPharmaceutical Science
23 / 183 87%

Journal Statistics

Bimonthly
Issues/Year
13 days avg. from submission to first decision 43 days avg. from submission to first post-review decision 10 days avg. from acceptance to online publication
Review Cycle
Article Processing Fee

Submission Information

Submission Website:

https://mc.manuscriptcentral.com/gdrt

Related Articles

Investigation of atmospheric pollution

Other

DOI: 10.1039/AN940650462A

Errata

Other

DOI: 10.1039/AN942670113A

Contents pages

Other

DOI: 10.1039/AN94267BX031

Legal notes

Other

DOI: 10.1039/AN943680115A

Back matter

Other

DOI: 10.1039/AN95277BP031

Notes

Other

DOI: 10.1039/AN942670225B

Legal notes

Other

DOI: 10.1039/AN940650221B

You might also like

Compound Q&A

What is Ethyl 3-cyclohexylpropanoate (CAS: 10094-36-7)?

Ethyl 3-cyclohexylpropanoate is a clear, colorless to light yellow liquid with a...

10094-36-7Ethyl 3-cyclohexylpr...
Compound Q&A

How should waste containing 2-(Hydroxymethyl)-5-(methoxycarbonyl)-6-methyl-4-(2-nitrophenyl)nicotinic acid (CAS: 34783-31-8) be handled?

Waste containing 2-(Hydroxymethyl)-5-(methoxycarbonyl)-6-methyl-4-(2-nitrophenyl...

34783-31-82-(Hydroxymethyl)-5-...
Compound Q&A

How should waste containing 2,4,6-Tris(pentafluoroethyl)-1,3,5-triazine (CAS: 858-46-8) be handled?

Waste containing 2,4,6-Tris(pentafluoroethyl)-1,3,5-triazine (CAS: 858-46-8) sho...

858-46-82,4,6-Tris(pentafluo...
Compound Q&A

What precautions should be taken when handling Chloroac-nle-oh (CAS: 56787-36-1)?

When handling Chloroac-nle-oh (CAS: 56787-36-1), it is essential to wear appropr...

56787-36-1Chloroac-nle-oh
Compound Q&A

What industries use Ethyl 6-phenylimidazo[2,1-b][1,3]thiazole-3-carboxylate (CAS: 752244-05-6)?

Ethyl 6-phenylimidazo[2,1-b][1,3]thiazole-3-carboxylate is primarily used in the...

752244-05-6Ethyl 6-phenylimidaz...
Compound Q&A

Are there alternatives to alpha-(2-Bromophenyl)benzylamine (CAS: 55095-15-3) in synthesis?

Alternatives to alpha-(2-Bromophenyl)benzylamine (CAS: 55095-15-3) in synthesis ...

55095-15-3alpha-(2-Bromophenyl...
Compound Q&A

How should waste containing 2-Chloro-5-methoxypyridine (CAS: 139585-48-1) be handled?

Waste containing 2-Chloro-5-methoxypyridine (CAS: 139585-48-1) should be managed...

139585-48-12-Chloro-5-methoxypy...
Compound Q&A

What industries use 1-(4-Methoxyphenyl)-2,5-dimethyl-1H-pyrrole (CAS: 5044-27-9)?

1-(4-Methoxyphenyl)-2,5-dimethyl-1H-pyrrole (CAS: 5044-27-9) is used in various ...

5044-27-91-(4-Methoxyphenyl)-...
Compound Q&A

Are there alternatives to 3-Bromo-5-(N-Boc)aminomethylisoxazole (CAS: 903131-45-3) in synthesis?

There are alternative reagents and compounds that can be used in the synthesis o...

903131-45-33-Bromo-5-(N-Boc)ami...
Compound Q&A

What is Tungsten(IV) oxide (CAS: 12036-22-5)?

Tungsten(IV) oxide, also known as tungsten dioxide, is a chemical compound with ...

12036-22-5Tungsten(IV) oxide
Disclaimer
This page provides academic journal information for reference and research purposes only. We are not affiliated with any journal publishers and do not handle publication submissions. For publication-related inquiries, please contact the respective journal publishers directly.
If you notice any inaccuracies in the information displayed, please contact us at support@chemtradehub.com. We will promptly review and address your concerns.